Skip to main content
. 2020 Oct 2;2020(10):CD013739. doi: 10.1002/14651858.CD013739

Paranjpe 2020.

Study characteristics
Methods

  • Study design: retrospective cohort

  • Type of publication: peer‐reviewed journal publication

  • Setting and dates: hospital, 14 March 2020‐11 April 2020

  • Country: USA

  • Language: English

  • Number of centres: 1

  • Trial registration number: NR
Participants

  • Number of participants: 2773 allocated (intervention = 786; comparator = 1987)

  • Age: NR

  • Gender: NR

  • Comorbidities: NR

  • Confounding factors: prior anticoagulation (proportion NR, but adjusted), surgery (NR), cancer (NR), antiplatelet use (NR), history of VTE (NR)

  • Type of ventilator support: intubation and mechanical ventilation


Inclusion criteria

  • COVID‐19 confirmed by a PCR test


Exclusion criteria

  • NR
Interventions

  • Intervention of interest: treatment‐dose anticoagulation (including oral, SC, or IV forms). There is no detail about dose and type of anticoagulant.

  • Comparator: without anticoagulation

  • Concomitant therapy: NR

  • Duration of follow‐up: NR (data reported from the period of hospitalisation)
Outcomes There is no differentiation between primary and secondary outcomes.

  • Mortality

  • Laboratorial parameters (blood routine characteristics, coagulation parameters, CPR levels)

  • Bleeding
Notes

  • Sponsor/funding: the work was supported by U54 TR001433‐05, National Center for Advancing Translational Sciences, National Institutes of Health

  • COIs: Dr. Fayad has received consulting fees from Alexion and GlaxoSmithKline; has received research funding from Daiichi‐Sankyo, Amgen, Bristol‐Myers Squibb, and Siemens Healthineers; and has received financial compensation as a board member and advisor to and owns equity as a co‐founder of Trained Therapeutix Discovery. Dr. Nadkarni has received financial compensation as a consultant and Advisory Board member for and owns equity in RenalytixAI; is a scientific co‐founder of RenalytixAI and Pensieve Health; has received operational funding from Goldfinch Bio; and has received consulting fees from BioVie Inc., AstraZeneca, Reata, and GLG consulting in the past 3 years. All other study authors have reported that they have no relationships relevant to the contents of this paper to disclose.